Cambodian and Australian Companies Launch ASEAN Plasma Joint Venture

[CEOCambodiaNews]

The Royal Group, Fresh Start Australia & Aegros Announce Joint Venture to Plasma Fragmentation in ASEAN
04/08/23 19:35

Phnom Penh (FN), Aug. 4 – On 3 August in Phnom Penh the leading companies of The Royal Group of Companies (Cambodia), Fresh Start (Australia) and Aegros (Australia) announced a partnership for the collection of Plasma throughout ASEAN and its fractionation into life saving products.

The world, especially Asia, has a shortage of Plasma products which is impacting the wellbeing of so many individuals across all counties. This partnership is a significant step in the progress of health development working towards a goal to give ASEAN counties more availability of Plasma treatment products.

Plasma is extracted from Blood and it has many important health uses including: a. Cancer treatments; b. Hemophilia Management; and c. many more medical treatments


Neak Oknha Kith Meng, chairman and CEO of Royal Group said that "the Joint Venture company will be called Royal Group Plasma Fractionation and will: a. collect Plasma across Asia; b. build a new plasma fractionation facility in Singapore at USD400 million to fractionate 1 million litres per year of the Asian plasma; and c. build a Fill & Finish facility in Cambodia to bottle, package and distribute plasma products".

Daniel Phillips, CEO of Fresh Start Australia Pty Ltd said that "the new Plazma framenation technology, created by Aegros Limited and called HaemaFracR will make Plasma products to: a produce urgently needed live saving plasma products to supply a grossly undersupplied ASEAN market and at an affordable cost; b. create new jobs in both Singapore and Cambodia; c. contribute to new export income/taxes for Singapore, Cambodia, and Australia; and d. place Singapore and Cambodia on the regional health leadership stage”.

Aegros Limited is a market innovator in health that saves and improves people's lives. It has changed an old industry that had not changed for over 70 years. Aegros will now bring its Australian technology across the World including Asia.

Co-Founder of Aegros Professor Hari Nair said today, "Our technology and IP will not just change the way Australia undertakes plasma fractionation but how plasma is fractionated globally. This deal represents Aegros' first overseas expansion and in another world first, will use plasma currently collected in Asia which cannot be processed by the existing fractionators."

"The Asian market represents approximately 60% of the world's population but only represents approximately 30% of the therapeutic plasma product sales. It is a grossly undersupplied market," John Manusu, co-founder said today.
https://en.freshnewsasia.com/index.php/ ... 07-40.html